1
|
Aijaz S, Peerwani G, Bugti A, Sheikh S, Mustaqeem M, Mal SB, Memon A, Khan G, Pathan A. Management and outcome of post-myocardial infarction ventricular septal rupture-A Low-Middle-Income Country Experience. PLoS One 2022; 17:e0276615. [PMID: 36301909 PMCID: PMC9612533 DOI: 10.1371/journal.pone.0276615] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2021] [Accepted: 10/10/2022] [Indexed: 11/06/2022] Open
Abstract
BACKGROUND Ventricular septal rupture (VSR) is a rare complication after acute myocardial infarction (AMI) especially in the reperfusion era but its associated mortality has remained high. This case series evaluated in-hospital and intermediate-term mortality in VSR patients. Additionally, we also analyzed risk factors, clinical presentation, intervention, and predictors of in-hospital mortality in VSR patients. METHODS Data of 67 patients with echocardiography confirmed diagnosis of VSR from January 2011 to April 2020 was extracted from hospital medical records. Records were also reviewed to document 30 day and 1-year mortality, recurrent heart failure admission, repeat myocardial infarction, and revascularization. In addition, telephonic follow-up was done to assess health-related quality of life(HRQOL) assessed by KCCQ-12. SCAI shock classification was used to categorize severity of cardiogenic shock. Univariate and multivariable logistic regression was used to determine predictors of in-hospital mortality. Survival function was presented using the Kaplan-Meier survival curve. RESULTS Mean age of patients was 62.7 ± 11.1 years, 62.7% were males. 65.7% of the patients presented more than 24 hours after MI and did not receive reperfusion therapy. Median time from AMI to VSR diagnosis was 2 (1-5) days. VSR closure was attempted in 53.7% patients. In-hospital mortality was 65.7%. At univariate level, predictors of in-hospital mortality were non-surgical management, basal VSR, right ventricular dysfunction, early VSR post-MI, and severe cardiogenic shock at admission (class C, D, or E). Adjusted predictors of in-hospital mortality included non-surgical management, basal VSR and advanced cardiogenic shock. There were 5 deaths during median followup of 44.1 months. HRQOL in patients available on followup was good (54.5%) or excellent (45.5%). CONCLUSION High in-hospital mortality was seen in VSR patients. VSR closure is the preferred treatment to get long-term survival, however, timing of repair as well as severity of cardiogenic shock plays a significant role in determining prognosis.
Collapse
Affiliation(s)
- Saba Aijaz
- Department of Clinical Research Cardiology, Tabba Heart Institute, Karachi, Pakistan
- Department of Clinical Cardiology, Tabba Heart Institute, Karachi, Pakistan
- * E-mail: ,
| | - Ghazal Peerwani
- Department of Clinical Research Cardiology, Tabba Heart Institute, Karachi, Pakistan
| | - Asadullah Bugti
- Department of Clinical Cardiology, Tabba Heart Institute, Karachi, Pakistan
| | - Sana Sheikh
- Department of Clinical Research Cardiology, Tabba Heart Institute, Karachi, Pakistan
| | - Marium Mustaqeem
- Department of Clinical Cardiology, Tabba Heart Institute, Karachi, Pakistan
| | - Sharwan Bhuro Mal
- Department of Clinical Cardiology, Tabba Heart Institute, Karachi, Pakistan
| | - Ahson Memon
- Department of Cardiac Surgery, Tabba Heart Institute, Karachi, Pakistan
| | - Ghufranullah Khan
- Department of Cardiac Surgery, Tabba Heart Institute, Karachi, Pakistan
| | - Asad Pathan
- Department of Clinical Research Cardiology, Tabba Heart Institute, Karachi, Pakistan
- Department of Clinical Cardiology, Tabba Heart Institute, Karachi, Pakistan
| |
Collapse
|
2
|
Increased Quality of Life Among Newly Diagnosed Patients With Heart Failure With Reduced Ejection Fraction in the Months After Initiation of Guideline-Directed Medical Therapy and Wearable Cardioverter Defibrillator Prescription. J Cardiovasc Nurs 2021; 36:589-594. [PMID: 34608886 DOI: 10.1097/jcn.0000000000000864] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
BACKGROUND The patient experience of heart failure involves a multi-impact symptom response with functional limitations, psychological changes, and significant treatment burden. OBJECTIVE The aim of this study was to examine the change in patient-reported outcomes in newly diagnosed patients with heart failure and reduced ejection fraction (HFrEF) prescribed a wearable cardioverter defibrillator. METHODS Adults hospitalized for new-onset heart failure, due to ischemic or nonischemic cardiomyopathy, and prescribed a wearable cardioverter defibrillator within 10 days post discharge were approached for inclusion. Participants completed the Kansas City Cardiomyopathy Questionnaire at 3 time points: baseline, day 90, and day 180. RESULTS A total of 210 patients (26% female) were included. All Kansas City Cardiomyopathy Questionnaire subscales (physical limitation, symptom frequency, quality of life, and social limitation) showed improvement from baseline to day 90 (all Ps < .001). Only quality of life continued to improve from day 90 to day 180 (P < .001). By day 90, nearly 70% of patients showed an improvement in quality of life (67.9%, n = 91), and by day 180, more than 80% (82.8%, n = 111) reported a net improvement. Five patients (3.7%) reported a net decrease, and 18 patients (13.4%) had no net change in quality of life during the 180-day period. CONCLUSION Patient-reported quality of life improved significantly among patients newly diagnosed with HFrEF and prescribed a wearable cardioverter defibrillator. These results suggest that pursuing guideline-directed medical therapy for HFrEF, while being protected by the wearable cardioverter defibrillator, is likely to provide symptom relief and improve quality of life.
Collapse
|
3
|
Saba MA, Goharpey S, Attarbashi Moghadam B, Salehi R, Afshani SM. Validation and responsiveness of the Persian version of HeartQoL questionnaire in cardiac rehabilitation after coronary artery bypass grafting: An observational study. ARYA ATHEROSCLEROSIS 2020; 16:170-177. [PMID: 33598037 PMCID: PMC7867308 DOI: 10.22122/arya.v16i4.2098] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/06/2020] [Accepted: 04/22/2020] [Indexed: 11/09/2022]
Abstract
BACKGROUND Decision making and the quality of care provided for chronic diseases have been shown to improve through patient participation. The HeartQoL questionnaire is a core health-related quality of life (HRQOL) tool specifically designed for individuals with ischemic heart disease (IHD) who have undergone interventions such as cardiac rehabilitation (CR). METHODS In this observational and multicenter study, 150 patients were recruited. The participants completed the HeartQoL, MacNew Heart Disease Questionnaire, and Short Form Health Survey (SF-36) on entering CR for validity assessment. The HeartQoL along with a Global Rating of Change (GRoC) scale (for responsiveness measurement) were completed by 100 participants 3 months later. RESULTS The mean age of all participants in validity assessment was 61.87 ± 8.13 years. Cronbach's alphas of the total scales ranged from 0.70 to 0.81 and of the subscales from 0.70 to 0.82. The Pearson correlation coefficient was used to determine construct validity; similar constructs were confirmed with correlation coefficients ranging from 0.50 to 0.69 and dissimilar constructs with correlation coefficients ranging from 0.28 to 0.29 (P < 0.010). The assessment of the responsiveness of the questionnaire indicated that the area under curve (AUC) was greater than 0.70 (range: 0.74 to 0.91) and the optimal cut-off point was 0.65. CONCLUSION The Persian version of the HeartQoL questionnaire demonstrated satisfactory psychometric properties in the sample of participants admitted to CR after coronary artery bypass grafting (CABG). The present study results showed that the HRQOL can be used by clinicians and researchers in conjunction with other outcome measures to gain additional information about symptoms relevant to HRQOL in patients referred to CR and to evaluate change over time.
Collapse
Affiliation(s)
- Maryam A. Saba
- PhD Candidate, Musculoskeletal Rehabilitation Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
| | - Shahin Goharpey
- Assistant Professor, Musculoskeletal Rehabilitation Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
| | - Behrouz Attarbashi Moghadam
- Associate Professor, Department of Physiotherapy, School of Rehabilitation, Tehran University of Medical Sciences, Tehran, Iran
| | - Reza Salehi
- Associate Professor, Rehabilitation Research Center, Department of Rehabilitation Management, School of Rehabilitation Sciences, Iran University of Medical Sciences, Tehran, Iran
| | - Sayed Mohammadreza Afshani
- Assistant Professor, Department of Cardiovascular Disease, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
| |
Collapse
|
4
|
Sehested TSG, Bjerre J, Ku S, Chang A, Jahansouz A, Owens DK, Hlatky MA, Goldhaber-Fiebert JD. Cost-effectiveness of Canakinumab for Prevention of Recurrent Cardiovascular Events. JAMA Cardiol 2020; 4:128-135. [PMID: 30649147 DOI: 10.1001/jamacardio.2018.4566] [Citation(s) in RCA: 51] [Impact Index Per Article: 12.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Importance In the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) trial, the anti-inflammatory monoclonal antibody canakinumab significantly reduced the risk of recurrent cardiovascular events in patients with previous myocardial infarction (MI) and high-sensitivity C-reactive protein (hs-CRP) levels of 2 mg/L or greater. Objective To estimate the cost-effectiveness of adding canakinumab to standard of care for the secondary prevention of major cardiovascular events over a range of potential prices. Design, Setting, and Participants A state-transition Markov model was constructed to estimate costs and outcomes over a lifetime horizon by projecting rates of recurrent MI, coronary revascularization, infection, and lung cancer with and without canakinumab treatment. We used a US health care sector perspective, and the base case used the current US market price of canakinumab of $73 000 per year. A hypothetical cohort of patients after MI aged 61 years with an hs-CRP level of 2 mg/L or greater was constructed. Interventions Canakinumab, 150 mg, administered every 3 months plus standard of care compared with standard of care alone. Main Outcomes and Measures Lifetime costs and quality-adjusted life-years (QALYs), discounted at 3% annually. Results Adding canakinumab to standard of care increased life expectancy from 11.31 to 11.36 years, QALYs from 9.37 to 9.50, and costs from $242 000 to $1 074 000, yielding an incremental cost-effectiveness ratio of $6.4 million per QALY gained. The price would have to be reduced by more than 98% (to $1150 per year or less) to meet the $100 000 per QALY willingness-to-pay threshold. These results were generally robust across alternative assumptions, eg, substantially lower health-related quality of life after recurrent cardiovascular events, lower infection rates while receiving canakinumab, and reduced all-cause mortality while receiving canakinumab. Including a potential beneficial effect of canakinumab on lung cancer incidence improved the incremental cost-effectiveness ratio to $3.5 million per QALY gained. A strategy of continuing canakinumab selectively in patients with reduction in hs-CRP levels to less than 2 mg/L would have a cost-effectiveness ratio of $819 000 per QALY gained. Conclusions and Relevance Canakinumab is not cost-effective at current US prices for prevention of recurrent cardiovascular events in patients with a prior MI. Substantial price reductions would be needed for canakinumab to be considered cost-effective.
Collapse
Affiliation(s)
- Thomas S G Sehested
- Department of Cardiovascular Epidemiology and Research, The Danish Heart Foundation, Copenhagen, Denmark.,Department of Cardiology, Copenhagen University Hospital Herlev and Gentofte, Copenhagen, Denmark
| | - Jenny Bjerre
- Department of Cardiology, Copenhagen University Hospital Herlev and Gentofte, Copenhagen, Denmark.,Department of Health Research and Policy, Stanford University School of Medicine, Stanford, California
| | - Seul Ku
- Department of Medicine, Stanford University, Stanford, California
| | - Andrew Chang
- Department of Medicine, Stanford University, Stanford, California
| | - Alison Jahansouz
- Department of Management Science and Engineering, Stanford University, Stanford, California
| | - Douglas K Owens
- VA Palo Alto Health Care System, Palo Alto, California.,Stanford Health Policy, Centers for Health Policy and Primary Care and Outcomes Research, Stanford University, Stanford, California
| | - Mark A Hlatky
- Department of Health Research and Policy, Stanford University School of Medicine, Stanford, California.,Department of Medicine, Stanford University, Stanford, California
| | - Jeremy D Goldhaber-Fiebert
- Stanford Health Policy, Centers for Health Policy and Primary Care and Outcomes Research, Stanford University, Stanford, California
| |
Collapse
|
5
|
Olliges E, Burgdorf C, Ladwig KH, Moeller C, Deftu-Kloes D, Pohl S, Ruettner B, Richardt G, Meissner K, Steger A, Goetzmann L, Ronel J. Psychosocial and physical long-term outcome in patients with a history of takotsubo cardiomyopathy or myocardial infarction - a multi-centered case control study. PSYCHOL HEALTH MED 2020; 25:989-1003. [PMID: 32000523 DOI: 10.1080/13548506.2020.1722315] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Physical long-term impacts of Takotsubo Cardiomyopathy (TTC) remain controversial and an underestimation of their severity becomes increasingly evident. Even less is known about mental long-term impacts of TTC. This study aims at a better understanding of the physical and mental long-term effects of TTC in comparison to myocardial infarctions (MI). On average 5 years after disease onset, 68 TTC patients and 68 age- and sex-matched MI patients were assessed for disease-related quality of life, depression, anxiety, chronic stress, social support, resilience, and life events prior to disease onset. Scores of TTC and MI patients were compared to each other and to normative references values. Regression analyses were used to evaluate the predictive value of the number of life events prior to disease onset for physical and mental long-term outcomes. Both groups displayed higher scores in depression and anxiety, higher levels of chronic stress, and lower scores in physical and mental quality of life in comparison to norm samples, while social support did not differ from norms. No differences between the two patient groups were observed. Within both groups, the majority of patients (TTC: 69.1%; MI: 60.3%) reported stressful life events prior to disease onset. In TTCs and MIs, the number of events had a significant impact on long-term mental health and chronic stress. Notably, both patient collectives scored higher in resilience than healthy controls. Results suggest negative long-term impacts of TTC on mental and physical wellbeing, comparable to those of MI. Besides a good somatic-medical care, psychotherapeutic support, including the development of functional coping strategies, might be warranted for TTC patients. The long-term impact of TTC should be taken as serious as that of MI.
Collapse
Affiliation(s)
- E Olliges
- Institute of Medical Psychology, Faculty of Medicine, LMU Munich , Munich, Germany.,Division of Health Promotion, Coburg University of Applied Sciences , Coburg, Germany
| | - C Burgdorf
- Department of Cardiology, Heart and Vascular Centre Bad Bevensen , Bad Bevensen, Germany
| | - K H Ladwig
- Department of Psychosomatic Medicine and Psychotherapy, Klinikum rechts der Isar, Techni- sche Universitaet Muenchen , Munich, Germany.,Department of Epidemiology II, Helmholtz Zentrum , Munich, Germany
| | - C Moeller
- Medical Clinic II, Luebeck, Universitaetsklinikum Schleswig-Holstein , Germany
| | - D Deftu-Kloes
- Department of Psychosomatic Medicine and Psychotherapy, Segeberger Kliniken , Bad Seg- eberg, Germany
| | - S Pohl
- Psychiatric Day-care Hospital, Klinikum Frankfurt (Oder) , Frankfurt Oder, Germany
| | - B Ruettner
- Department of Psychology, Medical School Hamburg , Germany
| | - G Richardt
- Department of Cardiology, Segeberger Kliniken , Bad Segeberg, Germany
| | - K Meissner
- Institute of Medical Psychology, Faculty of Medicine, LMU Munich , Munich, Germany.,Division of Health Promotion, Coburg University of Applied Sciences , Coburg, Germany
| | - A Steger
- Klinik und Poliklinik fuer Innere Medizin I, Klinikum rechts der Isar, Technische Universitaet Muenchen , Munich, Germany
| | - L Goetzmann
- Department of Psychosomatic Medicine and Psychotherapy, Segeberger Kliniken , Bad Seg- eberg, Germany
| | - J Ronel
- Department of Psychosomatic Medicine and Psychotherapy, Klinikum rechts der Isar, Techni- sche Universitaet Muenchen , Munich, Germany.,Department of Psychosomatic Medicine and Psychotherapy, Klinik Barmelweid AG , Barmel- weid, Switzerland
| |
Collapse
|
6
|
Jelin E, Wisløff T, Moe MC, Heiberg T. Psychometric properties of the National Eye Institute Visual Function Questionnaire (NEI-VFQ 25) in a Norwegian population of patients with neovascular age-related macular degeneration compared to a control population. Health Qual Life Outcomes 2019; 17:140. [PMID: 31412873 PMCID: PMC6692950 DOI: 10.1186/s12955-019-1203-0] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2018] [Accepted: 07/19/2019] [Indexed: 11/10/2022] Open
Abstract
Background Although visual acuity and optical coherence tomography (OCT) are most widely used as outcomes in treatment of neovascular age-related Macular Degeneration (nAMD), patient reported outcome measures are increasingly recognized. National Eye Institute Visual Function Questionnaire (NEI-VFQ 25) was developed to capture the perceived visual function. Yet, evidence of psychometric performance in the target population is required. The aim of this study was to examine the psychometric properties of NEI-VFQ 25 in a Norwegian cohort of newly diagnosed nAMD patients followed with a Treat and Extend (T/E) protocol. Methods Patients receiving intravitreal anti–vascular endothelial growth factor (anti-VEGF) injection treatment according to a T/E protocol completed a Norwegian translation of NEI-VFQ 25, EuroQoL Health Questionnaire (EQ-5D), and Patient acceptable symptom state (PASS 5) at baseline, 3, 6 and 12 months. In addition, a control population completed the same questionnaires. Visual acuity was assessed with LogMar for best/treated eye. Validity testing comprised face validity by a 0–10 numeric rating scale about relevance of NEI-VFQ 25 as well as regression analyses and correlations between NEI-VFQ 25 and other relevant variables. Reliability was examined with Intraclass Correlation Coefficient (ICC) and Cronbach’s alpha for internal consistency were performed. Responsiveness, discriminatory power and predictive value were also explored. Results Number of respondents at baseline, after 3, 6 and 12 months was 197, 186, 176 and 168, respectively. The control population comprised 26 individuals. Face validity of NEI-VFQ 25 had a mean (SD) of 7.8 (1.7) (n = 84). NEI-VFQ was significantly correlated to visual acuity and PASS 5 as well as EQ-5D at baseline. Reliability (ICC) of the overall and sub scores for the patients/controls ranged from 0.49–0.97/0.59–0.97. Cronbach’s alpha was 0.61–0.85. Discriminatory power was confirmed by significant differences of the overall score between controls and patients (P < 0.001). NEI-VFQ 25 indicates responsiveness showing overall score improved significantly (P ≤ 0.001) from baseline to 3 months. NEI-VFQ 25, general health and visual acuity at baseline were the strongest predictors for how patients reported vision after 6 months follow-up. Conclusion NEI-VFQ 25 showed acceptable psychometric performance, which supports that the Norwegian version can be used to monitor patients treated for nAMD.
Collapse
Affiliation(s)
- Elma Jelin
- Department of Ophthalmology, Oslo University Hospital, Postboks 4950 Nydalen, 0424, Oslo, Norway. .,Institute of Clinical Medicine, University of Oslo, Postboks 1171 Blindern, 0318, Oslo, Norway.
| | - Torbjørn Wisløff
- Norwegian Institute of Public Health, Postboks 222 Skøyen, 0213, Oslo, Norway.,Institute of Health and Society, University of Oslo, Oslo, Norway
| | - Morten C Moe
- Department of Ophthalmology, Oslo University Hospital, Postboks 4950 Nydalen, 0424, Oslo, Norway.,Institute of Clinical Medicine, University of Oslo, Postboks 1171 Blindern, 0318, Oslo, Norway
| | - Turid Heiberg
- Department of Regional Research Support, Oslo University Hospital, Sogn Arena, POBox 4950, Nydalen, N-0424, Oslo, Norway.,Faculty of Health and Welfare, Østfold University College, POBox 700, N-1757, Halden, Norway
| |
Collapse
|
7
|
Al Abdi RM, Alshraideh H, Hijazi HH, Jarrah M, Alyahya MS. The use of echocardiographic and clinical data recorded on admission to simplify decision making for elective percutaneous coronary intervention: a prospective cohort study. BMC Med Inform Decis Mak 2019; 19:46. [PMID: 30885191 PMCID: PMC6421658 DOI: 10.1186/s12911-019-0797-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2018] [Accepted: 03/07/2019] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Coronary artery disease (CAD), a leading cause of mortality, affects patient health-related quality of life (HRQoL). Elective percutaneous coronary interventions (ePCIs) are usually performed to improve HRQoL of CAD patients. The aim of this study was to design models using admission data to predict the outcomes of the ePCI treatments on the patients' HRQoL. METHODS This prospective cohort study was conducted with CAD patients who underwent ePCIs at the King Abdullah University Hospital in Jordan from January 2014 through May 2015. Six months after their ePCI procedures, the participants completed the improved MacNew (QLMI-2) questionnaire, which was used for evaluating three domains (physical, emotional and social) of HRQoL. Multivariate linear regression was used to design models to predict the three domains of HRQoL from echocardiographic findings and clinical data that are routinely measured on admission. RESULTS The study included 239 patients who underwent ePCIs and responded to the QLMI-2 questionnaire. The mean age (± standard deviation) of the participants was 55.74 ± 11.84 years, 54.58 ± 11.37 years for males (n = 174) and 59.11 ± 12.49 years for females (n = 65). The average scores for physical, emotional and social HRQoL were 4.38 ± 1.27, 4.4 ± 1.11, and 4.37 ± 1.32, respectively. Out of the 42 factors inputted to the models to predict HRQoL scores, 10, 9, and 9 factors were found to be significant determinants for physical, emotional and social domains, respectively, with adjusted coefficients of determination of 0.630, 0.604 and 0.534, respectively. Basophil levels on admission showed a significant positive correlation with the three domains of HRQoL, while aortic root diameter showed a negative correlation. Scores for the three domains were significantly lower in women than in men. Hypertensive and diabetic patients had significantly lower HRQoL scores than patients without hypertension and diabetes. CONCLUSION The prediction of HRQoL scores 6 months after an ePCI is possible based on data acquired on admission. The models developed here can be used as decision-making tools to guide physicians in identifying the efficacy of ePCIs for individual patients, hence decreasing the rate of inappropriate ePCIs and reducing costs and complications.
Collapse
Affiliation(s)
- Rabah M Al Abdi
- Biomedical Engineering Department, Faculty of Engineering, Jordan University of Science and Technology, Irbid, Jordan.
| | - Hussam Alshraideh
- Industrial Engineering Department, Faculty of Engineering, Jordan University of Science and Technology, Irbid, Jordan
| | - Heba H Hijazi
- Department of Health Management and Policy, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan
| | - Mohamad Jarrah
- Division of Cardiology, Internal Medicine Department, King Abdullah University Hospital, Jordan University of Science and Technology, Irbid, Jordan
| | - Mohammad S Alyahya
- Department of Health Management and Policy, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan
| |
Collapse
|
8
|
Kang K, Gholizadeh L, Han HR, Inglis SC. Predictors of health-related quality of life in korean patients with myocardial infarction: a longitudinal observational study. Heart Lung 2018; 47:142-148. [PMID: 29477416 DOI: 10.1016/j.hrtlng.2017.12.005] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2017] [Accepted: 12/18/2017] [Indexed: 01/10/2023]
Abstract
BACKGROUND Experience of myocardial infarction (MI) negatively affects different aspects of health-related quality of life (HRQoL). OBJECTIVES This study aimed to examine trends in HRQoL of MI patients and to identify demographic, clinical and psychosocial predictors of HRQoL at three months. METHODS A total of 150 patients in South Korea were completed the study questionnaires at baseline. After three months from discharge, 136 participants completed follow-up questionnaires, including the Korean version of the MacNew Quality of Life after Myocardial Infarction Questionnaire (MacNew). RESULTS HRQoL significantly improved over three months. Younger age, ST-elevation MI, and higher LVEF, lower level of depression, better understanding of the illness and higher perceived social support at baseline were associated with better HRQoL at three months. CONCLUSION Providing adequate information about the illness and social support as well as reducing negative psychological experiences in early days after MI may improve HRQoL of MI patients.
Collapse
Affiliation(s)
- Kyoungrim Kang
- University of Technology Sydney, Sydney, NSW, Australia.
| | | | - Hae-Ra Han
- The Johns Hopkins University, Baltimore, MD, USA
| | | |
Collapse
|
9
|
Bhatt AS, Ambrosy AP, Velazquez EJ. Adverse Remodeling and Reverse Remodeling After Myocardial Infarction. Curr Cardiol Rep 2017; 19:71. [DOI: 10.1007/s11886-017-0876-4] [Citation(s) in RCA: 97] [Impact Index Per Article: 13.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
|
10
|
Meroño O, Cladellas M, Ribas-Barquet N, Poveda P, Recasens L, Bazán V, García-García C, Ivern C, Enjuanes C, Orient S, Vila J, Comín-Colet J. El déficit de hierro es un determinante de la capacidad funcional y de la calidad de vida a los 30 días tras un síndrome coronario agudo. Rev Esp Cardiol 2017. [DOI: 10.1016/j.recesp.2016.09.040] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
|
11
|
Khoury H, Lavoie L, Welner S, Folkerts K. The Burden of Major Adverse Cardiac Events and Antiplatelet Prevention in Patients with Coronary or Peripheral Arterial Disease. Cardiovasc Ther 2017; 34:115-24. [PMID: 26670723 DOI: 10.1111/1755-5922.12169] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/27/2023] Open
Abstract
BACKGROUND Patients with a history of a cardiovascular (CV) disease are at high risk of suffering secondary major adverse cardiac events (MACE), namely death, nonfatal myocardial infarction (MI), stroke, symptomatic pulmonary embolism, CV and all-cause hospitalization, and bleeding. METHODS A comprehensive review of the literature was conducted to review the epidemiology and burden of MACE in patients with coronary or peripheral arterial disease (CAD or PAD) in Europe and other ex-US regions. Relevant articles published between 2003 and 2013 were retrieved from PubMed and other sites. RESULTS MACE incidence and prevalence in patients with CAD or PAD were increased by at least 1.4-fold compared with matched controls with no CV disease. In patients with CAD, MACE mostly occurred within 30 days of primary percutaneous coronary intervention; incidence decreased with time. Increased oxidative stress in coronary and peripheral arteries, diabetes, and chronic kidney disease were identified as the main risk factors for MACE in patients with CAD and PAD. Registry data showed that, although preventive antiplatelet therapy was prescribed at high rates, a large proportion (9-56%) of patients did not receive treatment. Furthermore, adherence to treatment declined over time, potentially leading to disease worsening. CONCLUSION Despite gaps in the literature, this assessment showed that MACE's risk is substantial among patients with CAD or PAD and that the use of preventive therapies is suboptimal. Development of additional preventive therapies for these patients is warranted.
Collapse
|
12
|
Iron Deficiency Is a Determinant of Functional Capacity and Health-related Quality of Life 30 Days After an Acute Coronary Syndrome. ACTA ACUST UNITED AC 2016; 70:363-370. [PMID: 27838349 DOI: 10.1016/j.rec.2016.10.004] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2016] [Accepted: 09/27/2016] [Indexed: 11/21/2022]
Abstract
BACKGROUND AND OBJECTIVES Iron deficiency (ID) is a prevalent condition in patients with ischemic heart disease and heart failure. Little is known about the impact of ID on exercise capacity and quality of life (QoL) in the recovery phase after an acute coronary syndrome (ACS). METHODS Iron status and its impact on exercise capacity and QoL were prospectively evaluated in 244 patients 30 days after the ACS. QoL was assessed by the standard EuroQoL-5 dimensions, EuroQoL visual analogue scale, and Heart-QoL questionnaires. Exercise capacity was analyzed by treadmill/6-minute walk tests. The effect of ID on cardiovascular mortality and readmission rate was also investigated. RESULTS A total of 46% of the patients had ID. These patients had lower exercise times (366±162 vs 462±155seconds; P<.001), metabolic consumption rates (7.9±2.9 vs 9.3±2.6 METS; P=.003), and EuroQoL-5 dimensions (0.76±0.25 vs 0.84±0.16), visual analogue scale (66±16 vs 72±17), and Heart-QoL (1.9±0.6 vs 2.2±0.6) scores (P<.05). ID independently predicted lower exercise times (OR, 2.9; 95%CI, 1.1-7.6; P=.023) and worse QoL (OR, 1.9; 95%CI, 1.1-3.3; P<.001) but had no effect on cardiovascular morbidity or mortality. CONCLUSIONS ID, a prevalent condition in ACS patients, results in a poorer mid-term functional recovery, as measured by exercise capacity and QoL.
Collapse
|
13
|
Helvik AS, Corazzini K, Selbæk G, Bjørkløf GH, Laks J, Šaltytė Benth J, Østbye T, Engedal K. Health-related quality of life in older depressed psychogeriatric patients: one year follow-up. BMC Geriatr 2016; 16:131. [PMID: 27388445 PMCID: PMC4936227 DOI: 10.1186/s12877-016-0310-6] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2016] [Accepted: 06/17/2016] [Indexed: 11/16/2022] Open
Abstract
Background Knowledge about long-term change in health related quality of life (HQoL) among older adults after hospitalization for treatment of depression has clinical relevance. The aim was firstly to describe the change of HQoL one year after admission for treatment of depression, secondly to explore if improved HQoL was associated with remission of depression at follow-up and lastly to study how HQoL in patients with remission from depression were compared to a reference group of older persons without depression. Method This study had the one year follow-up information of 108 older patients (≥60 years), all hospitalized for depression at baseline, and a reference sample of 106 community-living older adults (≥60 years) without depression. HQoL was measured using the EuroQol Group’s EQ-5D Index and a visual analog scale (EQ-VAS). Depression and remission were diagnosed according to ICD-10. Socio-demographic variables (age, gender, and education), depressive symptom score (Montgomery-Aasberg Depression Rating Scale), cognitive functioning (Mini Mental State Examination scale), instrumental activities of daily living (the Lawton and Brody’s Instrumental Activities of Daily Living Scale), and poor general physical health (General Medical Health Rating) were included as covariates. Results HQoL had improved at follow-up for the total group of depressed patients, as indicated by better scores on the EQ-5D Index and EQ-VAS. In the multivariate linear regression model, improved EQ-5D Index and EQ-VAS was significantly better in those with remission of depression and those with better baseline physical health. In adjusted analyses, the HQoL in patients with remission from depression at follow-up did not differ from the HQoL in a reference group without depression. Conclusion Older hospital patients with depression who experienced remission one year after admission gained HQoL and their HQoL was comparable with the HQoL in a reference group of older adults without depression when adjusting for differences in socio-demographics and health conditions.
Collapse
Affiliation(s)
- Anne-Sofie Helvik
- Department of Public Health and General Practice, Faculty of Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway. .,St. Olav's University Hospital, Trondheim, Norway. .,Norwegian National Advisory Unit on Aging and Health, Vestfold Health Trust, Tønsberg, Norway.
| | | | - Geir Selbæk
- Norwegian National Advisory Unit on Aging and Health, Vestfold Health Trust, Tønsberg, Norway.,Centre for Old Age Psychiatric Research, Innlandet Hospital Trust, Ottestad, Norway.,Faculty of Medicine, Institute of Health and Society, University of Oslo, Oslo, Norway
| | - Guro Hanevold Bjørkløf
- Norwegian National Advisory Unit on Aging and Health, Vestfold Health Trust, Tønsberg, Norway
| | - Jerson Laks
- Institute of Psychiatry, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.,Post Graduation Program in Translational Medicine, Universidade do Grande Rio (Unigranrio), Rio de Janeiro, Brazil
| | - Jūratė Šaltytė Benth
- Centre for Old Age Psychiatric Research, Innlandet Hospital Trust, Ottestad, Norway.,Institute of Clinical Medicine, Ahus Campus, University of Oslo, Oslo, Norway.,Research Centre, HØKH, Akershus University Hospital, Lørenskog, Norway
| | | | - Knut Engedal
- Norwegian National Advisory Unit on Aging and Health, Vestfold Health Trust, Tønsberg, Norway
| |
Collapse
|
14
|
Stevanović J, Pechlivanoglou P, Kampinga MA, Krabbe PFM, Postma MJ. Multivariate Meta-Analysis of Preference-Based Quality of Life Values in Coronary Heart Disease. PLoS One 2016; 11:e0152030. [PMID: 27011260 PMCID: PMC4806923 DOI: 10.1371/journal.pone.0152030] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2015] [Accepted: 03/08/2016] [Indexed: 11/17/2022] Open
Abstract
BACKGROUND There are numerous health-related quality of life (HRQol) measurements used in coronary heart disease (CHD) in the literature. However, only values assessed with preference-based instruments can be directly applied in a cost-utility analysis (CUA). OBJECTIVE To summarize and synthesize instrument-specific preference-based values in CHD and the underlying disease-subgroups, stable angina and post-acute coronary syndrome (post-ACS), for developed countries, while accounting for study-level characteristics, and within- and between-study correlation. METHODS A systematic review was conducted to identify studies reporting preference-based values in CHD. A multivariate meta-analysis was applied to synthesize the HRQoL values. Meta-regression analyses examined the effect of study level covariates age, publication year, prevalence of diabetes and gender. RESULTS A total of 40 studies providing preference-based values were detected. Synthesized estimates of HRQoL in post-ACS ranged from 0.64 (Quality of Well-Being) to 0.92 (EuroQol European"tariff"), while in stable angina they ranged from 0.64 (Short form 6D) to 0.89 (Standard Gamble). Similar findings were observed in estimates applying to general CHD. No significant improvement in model fit was found after adjusting for study-level covariates. Large between-study heterogeneity was observed in all the models investigated. CONCLUSIONS The main finding of our study is the presence of large heterogeneity both within and between instrument-specific HRQoL values. Current economic models in CHD ignore this between-study heterogeneity. Multivariate meta-analysis can quantify this heterogeneity and offers the means for uncertainty around HRQoL values to be translated to uncertainty in CUAs.
Collapse
Affiliation(s)
- Jelena Stevanović
- University of Groningen, Department of Pharmacy, Unit of Pharmacoepidemiology and Pharmacoeconomics (PE2), Groningen, The Netherlands
| | - Petros Pechlivanoglou
- Toronto Health Economics and Technology Assessment (THETA), Toronto, Canada.,University of Toronto, Faculty of Medicine, Institute of Health Policy, Management and Evaluation, Toronto, Canada
| | - Marthe A Kampinga
- University of Groningen, University Medical Center Groningen, Department of Cardiology, Thorax Center, Groningen, The Netherlands
| | - Paul F M Krabbe
- University of Groningen, University Medical Centre Groningen, Department of Epidemiology, Groningen, The Netherlands
| | - Maarten J Postma
- University of Groningen, Department of Pharmacy, Unit of Pharmacoepidemiology and Pharmacoeconomics (PE2), Groningen, The Netherlands
| |
Collapse
|
15
|
Wisløff T, Atar D. Cost-effectiveness of antiplatelet drugs after percutaneous coronary intervention. EUROPEAN HEART JOURNAL. QUALITY OF CARE & CLINICAL OUTCOMES 2015; 2:52-57. [PMID: 29474586 PMCID: PMC5862019 DOI: 10.1093/ehjqcco/qcv023] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/13/2015] [Indexed: 11/14/2022]
Abstract
Aims Clopidogrel has, for long time, been accepted as the standard treatment for patients who have undergone a percutaneous coronary intervention (PCI). The introduction of prasugrel-and more recently, ticagrelor-has introduced a decision-making problem for clinicians and governments worldwide: to use the cheaper clopidogrel or the more effective, and also more expensive prasugrel or ticagrelor. We aim to give helpful contributions to this debate by analysing the cost-effectiveness of clopidogrel, prasugrel, and ticagrelor compared with each other. Methods and results We modified a previously developed Markov model of cardiac disease progression. In the model, we followed up cohorts of patients who have recently had a PCI until 100 years or death. Possible events are revascularization, bleeding, acute myocardial infarction, and death. Our analysis shows that ticagrelor is cost-effective in 77% of simulations at an incremental cost-effectiveness ratio of €7700 compared with clopidogrel. Ticagrelor was also cost-effective against prasugrel at a cost-effectiveness ratio of €7800. Given a Norwegian cost-effectiveness threshold of €70 000, both comparisons appear to be clearly cost-effective in favour of ticagrelor. Conclusion Ticagrelor is cost-effective compared with both clopidogrel and prasugrel for patients who have undergone a PCI.
Collapse
Affiliation(s)
- Torbjørn Wisløff
- Oslo Centre for Biostatistics and Epidemiology, Oslo University Hospital & University of Oslo , Postboks 4950 Nydalen, Oslo 0424 , Norway
| | - Dan Atar
- Department of Cardiology, Oslo University Hospital, Ullevål, Norway.,Institute of Clinical Sciences, University of Oslo, Oslo, Norway
| |
Collapse
|
16
|
Staniūtė M, Vaškelytė J, Rumbinaitė E, Kaminskaitė B, Samsanavičienė S, Plungienė S, Brožaitienė J, Bunevičius R. Impact of left ventricular function on health-related quality of life in coronary artery disease patients. MEDICINA-LITHUANIA 2015; 51:233-9. [PMID: 26424188 DOI: 10.1016/j.medici.2015.07.005] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/16/2014] [Accepted: 07/13/2015] [Indexed: 01/20/2023]
Abstract
OBJECTIVE The aim of the study was to investigate the relation between health-related quality of life (HRQoL) and left ventricular systolic and diastolic function parameters in stable coronary artery disease (CAD) patients with mild and moderate heart failure. MATERIALS AND METHODS This study included 758 CAD patients. Left ventricular ejection fraction (LVEF) and ratio of peak velocities of early (E) and late (A) diastolic mitral inflow, ratio E/A, deceleration time, isovolumic relaxation time were assessed. Patients completed the SF-36 questionnaire. RESULTS There were no strong and significant associations between echocardiographic measures and HRQoL in NYHA I-II class patients. In NYHA III class in univariate linear regression analyses significant associations were found between LVEF and physical functioning (β=0.230, P=0.009) and role limitations due to physical problems (β=0.230, P=0.009) and these associations remain significant after adjustment for age, gender, hypertension, angina pectoris class, nitrate, ACE inhibitors and diuretics use. E/A ratio was significantly associated only with mental health domain (β=0.188, P=0.048), and this association remains significant after all adjustments. CONCLUSIONS In stable CAD patients with NYHA I-II functional class HRQoL was not strongly associated with left ventricular function; in NYHA III functional class patients' greater systolic function mainly was associated with better physical health and better diastolic function, with better mental health.
Collapse
Affiliation(s)
- Margarita Staniūtė
- Behavioral Medicine Institute, Medical Academy, Lithuanian University of Health Sciences, Palanga, Lithuania
| | - Jolanta Vaškelytė
- Department of Cardiology, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania
| | - Eglė Rumbinaitė
- Department of Cardiology, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania
| | - Birutė Kaminskaitė
- Department of Cardiology, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania
| | - Sigita Samsanavičienė
- Department of Cardiology, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania
| | - Sigita Plungienė
- Department of Cardiology, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania
| | - Julija Brožaitienė
- Behavioral Medicine Institute, Medical Academy, Lithuanian University of Health Sciences, Palanga, Lithuania.
| | - Robertas Bunevičius
- Behavioral Medicine Institute, Medical Academy, Lithuanian University of Health Sciences, Palanga, Lithuania
| |
Collapse
|
17
|
Factors influencing health-related quality of life after primary percutaneous coronary intervention for ST-elevation myocardial infarction. Appl Nurs Res 2015; 30:237-44. [PMID: 27091284 DOI: 10.1016/j.apnr.2015.09.002] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2014] [Revised: 08/27/2015] [Accepted: 09/06/2015] [Indexed: 12/17/2022]
Abstract
AIMS This study compared health-related quality of life (HRQOL) between patients aged ≥ 70 and <70 years at 4 weeks and 6 months after primary percutaneous coronary intervention (PPCI) and examined predictors of HRQOL. BACKGROUND HRQOL is an important patient outcome following PPCI for ST elevation myocardial infarction (STEMI) including pre-hospital field triage. METHODS A comparative cohort design was conducted on STEMI patients undergoing PPCI. HRQOL was measured using the Medical Outcomes Short Form-12 (SF-12) and the Seattle Angina Questionnaire (SAQ) at 4 weeks and 6 months post-PPCI. RESULTS HRQOL improved significantly from 4 weeks to 6 months in all aspects measured except anginal frequency and mental health. Patients aged ≥ 70 years had poorer physical HRQOL (SF-12) and physical limitations (SAQ), but better mental HRQOL (SF-12), angina frequency and QOL (SAQ) at both time points. Age, length of hospital stay, gender, partnership status and number of stents deployed are independent predictors of HRQOL improvement over time. CONCLUSION People ≥ 70 years reported better cardiac-specific quality of life, primarily from angina relief and improved mental function, despite worse physical limitations. HRQOL assessment is an important gauge of health status after PPCI for STEMI.
Collapse
|
18
|
Mishra RK, Yang W, Roy J, Anderson AH, Bansal N, Chen J, DeFilippi C, Delafontaine P, Feldman HI, Kallem R, Kusek JW, Lora CM, Rosas SE, Go AS, Shlipak MG. Kansas City Cardiomyopathy Questionnaire Score Is Associated With Incident Heart Failure Hospitalization in Patients With Chronic Kidney Disease Without Previously Diagnosed Heart Failure: Chronic Renal Insufficiency Cohort Study. Circ Heart Fail 2015; 8:702-8. [PMID: 25985796 DOI: 10.1161/circheartfailure.115.002097] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/21/2014] [Accepted: 05/15/2015] [Indexed: 01/09/2023]
Abstract
BACKGROUND Chronic kidney disease is a risk factor for heart failure (HF). Patients with chronic kidney disease without diagnosed HF have an increased burden of symptoms characteristic of HF. It is not known whether these symptoms are associated with occurrence of new onset HF. METHODS AND RESULTS We studied the association of a modified Kansas City Cardiomyopathy Questionnaire with newly identified cases of hospitalized HF among 3093 participants enrolled in the Chronic Renal Insufficiency Cohort (CRIC) Study who did not report HF at baseline. The annually updated Kansas City Cardiomyopathy Questionnaire score was categorized into quartiles (Q1-4) with the lower scores representing the worse symptoms. Multivariable-adjusted repeated measure logistic regression models were adjusted for demographic characteristics, clinical risk factors for HF, N-terminal probrain natriuretic peptide level and left ventricular hypertrophy, left ventricular systolic and diastolic dysfunction. Over a mean (±SD) follow-up period of 4.3±1.6 years, there were 211 new cases of HF hospitalizations. The risk of HF hospitalization increased with increasing symptom quartiles; 2.62, 1.85, 1.14, and 0.74 events per 100 person-years, respectively. The median number of annual Kansas City Cardiomyopathy Questionnaire assessments per participant was 5 (interquartile range, 3-6). The annually updated Kansas City Cardiomyopathy Questionnaire score was independently associated with higher risk of incident HF hospitalization in multivariable-adjusted models (odds ratio, 3.30 [1.66-6.52]; P=0.001 for Q1 compared with Q4). CONCLUSIONS Symptoms characteristic of HF are common in patients with chronic kidney disease and are associated with higher short-term risk for new hospitalization for HF, independent of level of kidney function, and other known HF risk factors.
Collapse
Affiliation(s)
- Rakesh K Mishra
- From the Division of Cardiology (R.K.M.) and Department of Epidemiology and Biostatistics (M.G.S.), University of California, San Francisco; Department of Biostatistics and Epidemiology (W.Y., J.R., A.H.A., H.I.F.), Renal, Electrolyte and Hypertension Division (R.K.), University of Pennsylvania, Philadelphia; Division of Nephrology, University of Washington, Seattle (N.B.); Departments of Nephrology and Hypertension (J.C.) and Medicine (P.D.), Tulane University, New Orleans, LA; Department of Medicine, University of Maryland, College Park (C.D.F.); National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD (J.W.K.); Division of Nephrology, University of Illinois, Champaign (C.M.L.); Joslin Diabetes Center and Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA (S.E.R.); Kaiser Permanente Division of Research, Oakland, CA (A.S.G.); and Department of Medicine, San Francisco Veterans Affairs Medical Center, CA (R.K.M., M.G.S.)
| | - Wei Yang
- From the Division of Cardiology (R.K.M.) and Department of Epidemiology and Biostatistics (M.G.S.), University of California, San Francisco; Department of Biostatistics and Epidemiology (W.Y., J.R., A.H.A., H.I.F.), Renal, Electrolyte and Hypertension Division (R.K.), University of Pennsylvania, Philadelphia; Division of Nephrology, University of Washington, Seattle (N.B.); Departments of Nephrology and Hypertension (J.C.) and Medicine (P.D.), Tulane University, New Orleans, LA; Department of Medicine, University of Maryland, College Park (C.D.F.); National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD (J.W.K.); Division of Nephrology, University of Illinois, Champaign (C.M.L.); Joslin Diabetes Center and Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA (S.E.R.); Kaiser Permanente Division of Research, Oakland, CA (A.S.G.); and Department of Medicine, San Francisco Veterans Affairs Medical Center, CA (R.K.M., M.G.S.)
| | - Jason Roy
- From the Division of Cardiology (R.K.M.) and Department of Epidemiology and Biostatistics (M.G.S.), University of California, San Francisco; Department of Biostatistics and Epidemiology (W.Y., J.R., A.H.A., H.I.F.), Renal, Electrolyte and Hypertension Division (R.K.), University of Pennsylvania, Philadelphia; Division of Nephrology, University of Washington, Seattle (N.B.); Departments of Nephrology and Hypertension (J.C.) and Medicine (P.D.), Tulane University, New Orleans, LA; Department of Medicine, University of Maryland, College Park (C.D.F.); National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD (J.W.K.); Division of Nephrology, University of Illinois, Champaign (C.M.L.); Joslin Diabetes Center and Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA (S.E.R.); Kaiser Permanente Division of Research, Oakland, CA (A.S.G.); and Department of Medicine, San Francisco Veterans Affairs Medical Center, CA (R.K.M., M.G.S.)
| | - Amanda H Anderson
- From the Division of Cardiology (R.K.M.) and Department of Epidemiology and Biostatistics (M.G.S.), University of California, San Francisco; Department of Biostatistics and Epidemiology (W.Y., J.R., A.H.A., H.I.F.), Renal, Electrolyte and Hypertension Division (R.K.), University of Pennsylvania, Philadelphia; Division of Nephrology, University of Washington, Seattle (N.B.); Departments of Nephrology and Hypertension (J.C.) and Medicine (P.D.), Tulane University, New Orleans, LA; Department of Medicine, University of Maryland, College Park (C.D.F.); National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD (J.W.K.); Division of Nephrology, University of Illinois, Champaign (C.M.L.); Joslin Diabetes Center and Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA (S.E.R.); Kaiser Permanente Division of Research, Oakland, CA (A.S.G.); and Department of Medicine, San Francisco Veterans Affairs Medical Center, CA (R.K.M., M.G.S.)
| | - Nisha Bansal
- From the Division of Cardiology (R.K.M.) and Department of Epidemiology and Biostatistics (M.G.S.), University of California, San Francisco; Department of Biostatistics and Epidemiology (W.Y., J.R., A.H.A., H.I.F.), Renal, Electrolyte and Hypertension Division (R.K.), University of Pennsylvania, Philadelphia; Division of Nephrology, University of Washington, Seattle (N.B.); Departments of Nephrology and Hypertension (J.C.) and Medicine (P.D.), Tulane University, New Orleans, LA; Department of Medicine, University of Maryland, College Park (C.D.F.); National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD (J.W.K.); Division of Nephrology, University of Illinois, Champaign (C.M.L.); Joslin Diabetes Center and Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA (S.E.R.); Kaiser Permanente Division of Research, Oakland, CA (A.S.G.); and Department of Medicine, San Francisco Veterans Affairs Medical Center, CA (R.K.M., M.G.S.)
| | - Jing Chen
- From the Division of Cardiology (R.K.M.) and Department of Epidemiology and Biostatistics (M.G.S.), University of California, San Francisco; Department of Biostatistics and Epidemiology (W.Y., J.R., A.H.A., H.I.F.), Renal, Electrolyte and Hypertension Division (R.K.), University of Pennsylvania, Philadelphia; Division of Nephrology, University of Washington, Seattle (N.B.); Departments of Nephrology and Hypertension (J.C.) and Medicine (P.D.), Tulane University, New Orleans, LA; Department of Medicine, University of Maryland, College Park (C.D.F.); National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD (J.W.K.); Division of Nephrology, University of Illinois, Champaign (C.M.L.); Joslin Diabetes Center and Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA (S.E.R.); Kaiser Permanente Division of Research, Oakland, CA (A.S.G.); and Department of Medicine, San Francisco Veterans Affairs Medical Center, CA (R.K.M., M.G.S.)
| | - Christopher DeFilippi
- From the Division of Cardiology (R.K.M.) and Department of Epidemiology and Biostatistics (M.G.S.), University of California, San Francisco; Department of Biostatistics and Epidemiology (W.Y., J.R., A.H.A., H.I.F.), Renal, Electrolyte and Hypertension Division (R.K.), University of Pennsylvania, Philadelphia; Division of Nephrology, University of Washington, Seattle (N.B.); Departments of Nephrology and Hypertension (J.C.) and Medicine (P.D.), Tulane University, New Orleans, LA; Department of Medicine, University of Maryland, College Park (C.D.F.); National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD (J.W.K.); Division of Nephrology, University of Illinois, Champaign (C.M.L.); Joslin Diabetes Center and Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA (S.E.R.); Kaiser Permanente Division of Research, Oakland, CA (A.S.G.); and Department of Medicine, San Francisco Veterans Affairs Medical Center, CA (R.K.M., M.G.S.)
| | - Patrice Delafontaine
- From the Division of Cardiology (R.K.M.) and Department of Epidemiology and Biostatistics (M.G.S.), University of California, San Francisco; Department of Biostatistics and Epidemiology (W.Y., J.R., A.H.A., H.I.F.), Renal, Electrolyte and Hypertension Division (R.K.), University of Pennsylvania, Philadelphia; Division of Nephrology, University of Washington, Seattle (N.B.); Departments of Nephrology and Hypertension (J.C.) and Medicine (P.D.), Tulane University, New Orleans, LA; Department of Medicine, University of Maryland, College Park (C.D.F.); National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD (J.W.K.); Division of Nephrology, University of Illinois, Champaign (C.M.L.); Joslin Diabetes Center and Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA (S.E.R.); Kaiser Permanente Division of Research, Oakland, CA (A.S.G.); and Department of Medicine, San Francisco Veterans Affairs Medical Center, CA (R.K.M., M.G.S.)
| | - Harold I Feldman
- From the Division of Cardiology (R.K.M.) and Department of Epidemiology and Biostatistics (M.G.S.), University of California, San Francisco; Department of Biostatistics and Epidemiology (W.Y., J.R., A.H.A., H.I.F.), Renal, Electrolyte and Hypertension Division (R.K.), University of Pennsylvania, Philadelphia; Division of Nephrology, University of Washington, Seattle (N.B.); Departments of Nephrology and Hypertension (J.C.) and Medicine (P.D.), Tulane University, New Orleans, LA; Department of Medicine, University of Maryland, College Park (C.D.F.); National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD (J.W.K.); Division of Nephrology, University of Illinois, Champaign (C.M.L.); Joslin Diabetes Center and Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA (S.E.R.); Kaiser Permanente Division of Research, Oakland, CA (A.S.G.); and Department of Medicine, San Francisco Veterans Affairs Medical Center, CA (R.K.M., M.G.S.)
| | - Radhakrishna Kallem
- From the Division of Cardiology (R.K.M.) and Department of Epidemiology and Biostatistics (M.G.S.), University of California, San Francisco; Department of Biostatistics and Epidemiology (W.Y., J.R., A.H.A., H.I.F.), Renal, Electrolyte and Hypertension Division (R.K.), University of Pennsylvania, Philadelphia; Division of Nephrology, University of Washington, Seattle (N.B.); Departments of Nephrology and Hypertension (J.C.) and Medicine (P.D.), Tulane University, New Orleans, LA; Department of Medicine, University of Maryland, College Park (C.D.F.); National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD (J.W.K.); Division of Nephrology, University of Illinois, Champaign (C.M.L.); Joslin Diabetes Center and Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA (S.E.R.); Kaiser Permanente Division of Research, Oakland, CA (A.S.G.); and Department of Medicine, San Francisco Veterans Affairs Medical Center, CA (R.K.M., M.G.S.)
| | - John W Kusek
- From the Division of Cardiology (R.K.M.) and Department of Epidemiology and Biostatistics (M.G.S.), University of California, San Francisco; Department of Biostatistics and Epidemiology (W.Y., J.R., A.H.A., H.I.F.), Renal, Electrolyte and Hypertension Division (R.K.), University of Pennsylvania, Philadelphia; Division of Nephrology, University of Washington, Seattle (N.B.); Departments of Nephrology and Hypertension (J.C.) and Medicine (P.D.), Tulane University, New Orleans, LA; Department of Medicine, University of Maryland, College Park (C.D.F.); National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD (J.W.K.); Division of Nephrology, University of Illinois, Champaign (C.M.L.); Joslin Diabetes Center and Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA (S.E.R.); Kaiser Permanente Division of Research, Oakland, CA (A.S.G.); and Department of Medicine, San Francisco Veterans Affairs Medical Center, CA (R.K.M., M.G.S.)
| | - Claudia M Lora
- From the Division of Cardiology (R.K.M.) and Department of Epidemiology and Biostatistics (M.G.S.), University of California, San Francisco; Department of Biostatistics and Epidemiology (W.Y., J.R., A.H.A., H.I.F.), Renal, Electrolyte and Hypertension Division (R.K.), University of Pennsylvania, Philadelphia; Division of Nephrology, University of Washington, Seattle (N.B.); Departments of Nephrology and Hypertension (J.C.) and Medicine (P.D.), Tulane University, New Orleans, LA; Department of Medicine, University of Maryland, College Park (C.D.F.); National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD (J.W.K.); Division of Nephrology, University of Illinois, Champaign (C.M.L.); Joslin Diabetes Center and Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA (S.E.R.); Kaiser Permanente Division of Research, Oakland, CA (A.S.G.); and Department of Medicine, San Francisco Veterans Affairs Medical Center, CA (R.K.M., M.G.S.)
| | - Sylvia E Rosas
- From the Division of Cardiology (R.K.M.) and Department of Epidemiology and Biostatistics (M.G.S.), University of California, San Francisco; Department of Biostatistics and Epidemiology (W.Y., J.R., A.H.A., H.I.F.), Renal, Electrolyte and Hypertension Division (R.K.), University of Pennsylvania, Philadelphia; Division of Nephrology, University of Washington, Seattle (N.B.); Departments of Nephrology and Hypertension (J.C.) and Medicine (P.D.), Tulane University, New Orleans, LA; Department of Medicine, University of Maryland, College Park (C.D.F.); National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD (J.W.K.); Division of Nephrology, University of Illinois, Champaign (C.M.L.); Joslin Diabetes Center and Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA (S.E.R.); Kaiser Permanente Division of Research, Oakland, CA (A.S.G.); and Department of Medicine, San Francisco Veterans Affairs Medical Center, CA (R.K.M., M.G.S.)
| | - Alan S Go
- From the Division of Cardiology (R.K.M.) and Department of Epidemiology and Biostatistics (M.G.S.), University of California, San Francisco; Department of Biostatistics and Epidemiology (W.Y., J.R., A.H.A., H.I.F.), Renal, Electrolyte and Hypertension Division (R.K.), University of Pennsylvania, Philadelphia; Division of Nephrology, University of Washington, Seattle (N.B.); Departments of Nephrology and Hypertension (J.C.) and Medicine (P.D.), Tulane University, New Orleans, LA; Department of Medicine, University of Maryland, College Park (C.D.F.); National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD (J.W.K.); Division of Nephrology, University of Illinois, Champaign (C.M.L.); Joslin Diabetes Center and Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA (S.E.R.); Kaiser Permanente Division of Research, Oakland, CA (A.S.G.); and Department of Medicine, San Francisco Veterans Affairs Medical Center, CA (R.K.M., M.G.S.)
| | - Michael G Shlipak
- From the Division of Cardiology (R.K.M.) and Department of Epidemiology and Biostatistics (M.G.S.), University of California, San Francisco; Department of Biostatistics and Epidemiology (W.Y., J.R., A.H.A., H.I.F.), Renal, Electrolyte and Hypertension Division (R.K.), University of Pennsylvania, Philadelphia; Division of Nephrology, University of Washington, Seattle (N.B.); Departments of Nephrology and Hypertension (J.C.) and Medicine (P.D.), Tulane University, New Orleans, LA; Department of Medicine, University of Maryland, College Park (C.D.F.); National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD (J.W.K.); Division of Nephrology, University of Illinois, Champaign (C.M.L.); Joslin Diabetes Center and Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA (S.E.R.); Kaiser Permanente Division of Research, Oakland, CA (A.S.G.); and Department of Medicine, San Francisco Veterans Affairs Medical Center, CA (R.K.M., M.G.S.).
| | | |
Collapse
|
19
|
Conducting Quality of Life Research in People With Coronary Artery Disease in Non–English-Speaking Countries. J Cardiovasc Nurs 2015; 30:74-84. [DOI: 10.1097/jcn.0000000000000116] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
20
|
Smith DW, Davies EW, Wissinger E, Huelin R, Matza LS, Chung K. A systematic literature review of cardiovascular event utilities. Expert Rev Pharmacoecon Outcomes Res 2013; 13:767-90. [PMID: 24175732 DOI: 10.1586/14737167.2013.841545] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Cardiovascular disease (CVD) results in half of the non-communicable disease-related deaths worldwide. Rising treatment costs have increased the need for cost-utility models designed to compare the value of new and existing therapies. Cost-utility models require utilities, values representing the strength of preferences for various health states. This systematic literature review aimed to identify and evaluate utilities reported for stroke, myocardial infarction (MI) and angina. In total, 83 unique studies were identified that reported utilities for these events. Approximately two-thirds reported utility values for stroke, and most used the EuroQoL five dimension to derive utilities. Utility values were lower in patients who experienced cardiovascular (CV) events than in patients who did not. The utility estimates for each condition varied greatly, likely due to differences in assessment methodologies and patient populations. This variability must be considered when choosing values for cost-utility models. Comparisons among reported utilities are further complicated by inconsistent CV event definitions.
Collapse
Affiliation(s)
- Donald W Smith
- Evidera, 430 Bedford St. Suite 300 Lexington, MA 02420, USA
| | | | | | | | | | | |
Collapse
|
21
|
Stauber S, Schmid JP, Saner H, Znoj H, Saner G, Grolimund J, von Känel R. Health-Related Quality of Life is Associated with Positive Affect in Patients with Coronary Heart Disease Entering Cardiac Rehabilitation. J Clin Psychol Med Settings 2012; 20:79-87. [DOI: 10.1007/s10880-012-9311-6] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
22
|
Bøhmer E, Kristiansen IS, Arnesen H, Halvorsen S. Health and cost consequences of early versus late invasive strategy after thrombolysis for acute myocardial infarction. ACTA ACUST UNITED AC 2011; 18:717-23. [DOI: 10.1177/1741826711398425] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Affiliation(s)
- Ellen Bøhmer
- Department of Medicine, Innlandet Hospital Trust, Lillehammer, Norway
- Department of Cardiology, Oslo University Hospital, Ulleval, Oslo, Norway
| | | | - Harald Arnesen
- Center for Clinical Heart Research,Oslo University Hospital,Ulleval, Oslo, Norway
- Faculty of Medicine, University of Oslo, Oslo, Norway
| | - Sigrun Halvorsen
- Department of Cardiology, Oslo University Hospital, Ulleval, Oslo, Norway
| |
Collapse
|
23
|
Miller CD. How little we know: the search for a simple answer on acute beta-blocker use in the management of acute coronary syndrome. Acad Emerg Med 2010; 17:93-5. [PMID: 20078441 DOI: 10.1111/j.1553-2712.2009.00629.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
24
|
Norekvål TM, Fridlund B, Moons P, Nordrehaug JE, Saevareid HI, Wentzel-Larsen T, Hanestad BR. Sense of coherence--a determinant of quality of life over time in older female acute myocardial infarction survivors. J Clin Nurs 2009; 19:820-31. [PMID: 19732247 DOI: 10.1111/j.1365-2702.2009.02858.x] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
AIMS To determine the relationships between different sense of coherence levels and quality of life, and in older female myocardial infarction survivors; to investigate how socio-demographic, clinical characteristics, sense of coherence self-reported symptoms and function affect quality of life; and to determine whether sense of coherence and quality of life are stable during a six-month follow-up. BACKGROUND Myocardial infraction confers new physical and mental challenges. However, research on sense of coherence and other factors involved in maintaining physical, psychosocial and environmental aspects of quality of life in older female myocardial infraction survivors is scant. DESIGN Survey. METHODS A postal survey was conducted of 145 women, aged 62-80 years, three months to five years after myocardial infarction (T1), with a follow-up after six months (T2). Self-reported socio-demographic and clinical data and hospital medical records data were collected. The sense of coherence scale (SOC-29) and the World Health Organization Quality of Life Instrument Abbreviated (WHOQOL-BREF) were used. RESULTS We found a significant difference in quality of life between weak, moderate, and strong sense of coherence groups (p<0.001). Sense of coherence contributed to the level of all quality of life domains (p<0.001). Several clinical characteristics contributed to quality of life: (1) physical domain: comorbidities (p<0.001), previous myocardial infarction (p = 0.013), ejection fraction (p<0.011), length of hospital stay (p = 0.005) symptoms and function (p<0.001); (2) psychological domain: previous myocardial infarction (p = 0.031) and symptoms and function (p<0.001); and (3) environmental domain: education (p = 0.033) and symptoms and function (p = 0.003). On group level, both sense of coherence and quality of life were stable. Experiencing specific health changes (p<0.001), not major life events, influenced quality of life during the six-month follow-up. CONCLUSION Sense of coherence was an important stable determinant of quality of life domains in female myocardial infarction survivors. Although other factors were identified, further research is needed to elucidate additional determinants of quality of life. RELEVANCE TO CLINICAL PRACTICE These specific factors could guide clinicians in making treatment decisions that optimize the quality of life of their patients. Applying a salutogenic perspective through patient education may be important.
Collapse
Affiliation(s)
- Tone M Norekvål
- Department of Heart Disease, Haukeland University Hospital and University of Bergen, Bergen, Norway.
| | | | | | | | | | | | | |
Collapse
|